Hematopoietic stem cell transplantation for infantile osteopetrosis Journal Article


Authors: Orchard, P. J.; Fasth, A. L.; Le Rademacher, J. L.; He, W.; Boelens, J. J.; Horwitz, E. M.; Al-Seraihy, A.; Ayas, M.; Bonfim, C. M.; Boulad, F.; Lund, T.; Buchbinder, D. K.; Kapoor, N.; Obrien, T. A.; Perez, M. A. D.; Veys, P. A.; Eapen, M.
Article Title: Hematopoietic stem cell transplantation for infantile osteopetrosis
Abstract: We report the international experience in outcomes after related and unrelated hematopoietic transplantation for infantile osteopetrosis in 193 patients. Thirty-four percent of transplants used grafts from HLA-matched siblings, 13% from HLA-mismatched relatives, 12% from HLA-matched, and 41% from HLA-mismatched unrelated donors. The median age at transplantation was 12 months. Busulfan and cyclophosphamide was the most common conditioning regimen. Long-termsurvival was higher afterHLA-matched sibling compared to alternative donor transplantation. There were no differences in survival after HLAmismatched related, HLA-matched unrelated, or mismatched unrelated donor transplantation. The 5- and 10-year probabilities of survival were 62% and 62% after HLA-matched siblingand42%and39%after alternative donor transplantation (P5.01 andP5.002, respectively). Graft failurewasthemostcommon cause of death, accounting for50%of deaths after HLA-matched sibling and43%of deaths after alternative donor transplantation. The day-28 incidence of neutrophil recovery was 66% after HLA-matched sibling and 61% after alternative donor transplantation (P5.49). The median age of surviving patients is 7 years. Of evaluable surviving patients,70%are visually impaired;10%have impaired hearing and gross motor delay. Nevertheless, 65% reported performance scores of 90 or 100, and in 17%, a score of 80 at last contact. Most survivors >5 years are attending mainstream or specialized schools. Rates of veno-occlusive disease and interstitial pneumonitis were high at 20%. Though allogeneic transplantation results in long-term survival with acceptable social function, strategies to lower graft failure and hepatic and pulmonary toxicity are urgently needed. © 2015 by The American Society of Hematology.
Journal Title: Blood
Volume: 126
Issue: 2
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2015-07-09
Start Page: 270
End Page: 276
Language: English
DOI: 10.1182/blood-2015-01-625541
PROVIDER: scopus
PMCID: PMC4497967
PUBMED: 26012570
DOI/URL:
Notes: Export Date: 2 September 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Farid Boulad
    329 Boulad